CANCER DRIVER INTERCEPTION, Systemic Inflammation, Gut Dysbiosis, Genomic Instability, Immune System Deficiency, PRENATAL SCREENING, G-TEST, ULTRANIPT , ULTRANIPT DG, OMNIPT, Inherited Metabolic Disorder, Severe Combined Immunodeficiency, Lysosomal Storage Diseases, CANCER EARLY DETECTION, Solid Cancer, Breast and Ovary, Lung, Colon and rectum, Genome Instability, AESTHETICS STEM CELLS, Skin Rejuvenation, Face Reshaping, Breast augmentation, Buttock enhancement, Scar Reduction, Hair Loss, Female rejuvenation, Penis enlargment, HEREDITARY CANCERS DRIVERS, Endometrium, Colon, Solid Cancers, Breast and Ovary, REGENERATIVE STEM CELLS, Orthopedics, Premature Ovarian Failure, Erectile dysfunction, Anti-aging Therapy iV, Empty Nose Syndrome, Body Performance, Supportive Care, CANCER DIAGNOSIS, Colon and Rectum, Breast, Ovary and Prostate, Lung Cancer Assay, Liquid Biopsy, STEM CELL EXOSOMES, Skin Aging, Hair Loss, Orthopedics, Erectile Dysfunction, Female Rejuvenation, Body Performance, Anti-Ageing, PREVENTIVE CANCER THERAPY, Systemic Inflammation, Dysbiosis, Genomic Instability, Immune Deficiency, STEM CELL BANKING, Cord Blood Derived, Cord Tissue Derived, Adipose Tissue Derived, EXOSOME COSMETICS, X-FILL – Eye & Lip Contour, X-LIFT – Firm Facial Lifting, X-SKIN- Advanced Moisturizing, X-HAIR – Hair Loss Treatment
Skip to main content

Solid Tumor Interception

HELIXPAN

Solid Tumor Interception

HELIXPAN is a prevention program aimed at evaluating the prodromal phase of solid tumors, except for those of the brain. With the annual repetition of the HELIXPAN test, the monitoring of somatic mutations is carried out and, therefore, genomic stability is kept under control which, when it is lacking, may lead to the onset of cancer

Indications

The HELIXPAN test is suitable for anyone who does not live in conditions of environmental pollution, leads healthy lifestyles and has no reason to access targeted prevention programs.

What the test evaluates

The HELIXPAN test can detect genetic instability (or genomic instability), evaluated by monitoring the frequency of somatic mutations, the main indicator of the prodromal phase of solid tumors.

An innovative model

With the Helixafe program, it is possible to evaluate objective parameters, such as somatic or acquired mutations, which can be analyzed using the most modern techniques of liquid biopsy and sequencing (Next Generation Sequencing). Thanks to NGS, it is possible to monitor the mutation frequencies in the patient and then analyze the genomic instability through the algorithm patented by the Bioscience Institute.

How the test is performed

Bioscience Institute offers pre-test advice and provides all useful information about the HELIXAFE prevention program and the execution of the HELIXPAN test.

The test involves a simple blood sample that can be performed at one of our reference centers or through your doctor.

The Bioscience Institute laboratories extract the DNA present in the sample and sequence it using the advanced Next Generation Sequencing (NGS) techniques. The subsequent bioinformatics analysis allows the determination of the presence of any mutations in the genes under examination.

Test results are available in approximately 30 days.

Request HELIXPAN

Request the HELIXPAN test to know your level of genomic stability.

Email info@bioinst.com or fill out the form below to be contacted by one of our experts

(*) Required fields






    How did you hear about us? InternetDoctor/OncologistMagazines/NewspapersRelatives/FriendsOther

    Privacy Policy (*)

    ×

    Information Request








      Privacy Policy (*)